Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Sea (SE – Research Report), VTEX (VTEX – Research Report) and Akamai (AKAM – Research Report).
Sea (SE)
In a report released today, Venugopal Garre from Bernstein maintained a Buy rating on Sea, with a price target of $65.00. The company’s shares closed last Tuesday at $44.51.
According to TipRanks.com, Garre is ranked #7682 out of 8601 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sea with a $63.65 average price target, representing a 41.5% upside. In a report issued on October 24, Bank of America Securities also maintained a Buy rating on the stock with a $55.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
VTEX (VTEX)
KeyBanc analyst Michael Turits maintained a Hold rating on VTEX today. The company’s shares closed last Tuesday at $5.86.
According to TipRanks.com, Turits is a top 100 analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VTEX with a $6.56 average price target.
Akamai (AKAM)
KeyBanc analyst Thomas Blakey reiterated a Buy rating on Akamai today and set a price target of $134.00. The company’s shares closed last Tuesday at $108.86, close to its 52-week high of $111.32.
According to TipRanks.com, Blakey is a 1-star analyst with an average return of
Currently, the analyst consensus on Akamai is a Moderate Buy with an average price target of $113.71, implying a 3.8% upside from current levels. In a report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $120.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SE:
- Sea Limited call volume above normal and directionally bullish
- Sea Limited price target raised to $55 from $53 at BofA
- Sea Limited price target lowered to $49 from $50 at Citi
- Cantor biotech/biopharma analysts to hold an analyst/industry conference call
- Unusually active option classes on open September 27th
